NCT06182969 A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
| NCT ID | NCT06182969 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Ascentage Pharma Group Inc. |
| Condition | SLE |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-08-09 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2024-08-09 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
Eligibility Criteria
Inclusion Criteria: * 1\. Diagnosis of systemic lupus erythematosus for at least 6 months. * 2\. On stable treatment for systemic lupus erythematosus before first dose at least 28 days. * 3\. SLEDIA-2000 score: 4-12 * 4.Other than systemic lupus erythematosus, subject should be in general good health. Exclusion Criteria: * 1\. Severe systemic lupus erythematosus. * 2\. Significant autoimmune disease other than lupus. * 3\. Significant, uncontrolled or unstable disease in any organ.
Contact & Investigator
Sheng Chen, Ph.D
PRINCIPAL INVESTIGATOR
Renji Hospital Shanghai Jiaotong University School of Medical
Frequently Asked Questions
Who can join the NCT06182969 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying SLE. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06182969 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06182969 currently recruiting?
Yes, NCT06182969 is actively recruiting participants. Contact the research team at Yzhai@ascentage.com for enrollment information.
Where is the NCT06182969 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06182969 clinical trial?
NCT06182969 is sponsored by Ascentage Pharma Group Inc.. The principal investigator is Sheng Chen, Ph.D at Renji Hospital Shanghai Jiaotong University School of Medical. The trial plans to enroll 40 participants.